Navigation Links
Insulet Reports First Quarter 2008 Results
Date:5/13/2008

let is dependent; Insulet's ability to obtain favorable reimbursement from third-party payors for the OmniPod System and potential adverse changes in reimbursement rates or policies relating to the OmniPod; potential adverse effects resulting from competition with competitors; technological innovations adversely affecting the Company's business; the Company's ability to integrate Dexcom's technology into its product; potential termination of Insulet's license to incorporate a blood glucose meter into the OmniPod System; Insulet's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; adverse regulatory or legal actions relating to the OmniPod System; the potential violation of federal or state laws prohibiting "kickbacks" and false and fraudulent claims or adverse affects of challenges to or investigations into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet; unfavorable results of clinical studies relating to the OmniPod System or the products of Insulet's competitors; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to Insulet's products; Insulet's ability to attract and retain key personnel; Insulet's ability to manage its growth; risks associated with potential future acquisitions; Insulet's ability to maintain compliance with the restrictions and covenants contained in its existing credit and security agreement; Insulet's ability to successfully maintain effective internal controls; and other risks and uncertainties described in the section of its Annual Report on Form 10-K, dated March 18, 2008, which was filed with the Securities and Exchange Commission on March 20, 2008 entitled "Risk Factors" and its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize,
'/>"/>
SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
2. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... MINNEAPOLIS , Nov. 25, 2014 Bio-Techne ... it has appointed Robert Gavin to serve ... of the Protein Platforms Division.  Mr. Gavin will be ... business segment, which includes the ProteinSimple business acquired in ... San Jose, California -based ProteinSimple ...
(Date:11/24/2014)... , UAE, November 24, 2014 ... "Sheikh Hamdan Bin Rashid Al Maktoum Awards for Medical ... Dubai, United Arab Emirates , on ... ) , The Carter Center which ... Services is actively involved in numerous programs that aim ...
(Date:11/24/2014)... SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2014 /PRNewswire/ ... announced that Bonnie H. Anderson , president and chief ... the Piper Jaffray 26 th Annual Healthcare Conference on ... New York . The live audio ... website at http://investor.veracyte.com . Please connect to the website ...
(Date:11/24/2014)... The new video, “ Save Time ... how to reduce the number of instruments on ... design can be complicated, requiring multiple chemical measurements ... and deposition. Dedicated single and dual channel transmitters ... space. Additionally, installing and maintaining each transmitter, its ...
Breaking Biology Technology:Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Five US Winners Among Recipients of Hamdan Medical Awards 2Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2
... AGREEMENT PROVIDES CORGENIX EXCLUSIVE WORLDWIDE RIGHTS TO ... FOR CARDIOVASCULAR INFLAMMATION, DENVER, March 18 ... a worldwide developer and marketer of,diagnostic test ... the Okayama,Prefecture Industrial Promotion Foundation covering new ...
... N.J., March 18 Centocor,Inc. and Schering-Plough ... that a,Marketing Authorization Application (MAA) has been ... the approval of golimumab (CNTO,148) as a ... psoriatic arthritis and ankylosing spondylitis. The initial,submission ...
... Diagnostics -, SUNNYVALE, Calif., March 18 ... today announced that Linda,McAllister, M.D., Ph.D., has joined ... a new position. Dr. McAllister has recent,experience in ... as in,clinical medicine and academic research, where her ...
Cached Biology Technology:Corgenix Signs Technology Licensing Agreement With Japanese Government 2Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6Dr. Linda McAllister Joins Arbor Vita Corporation as Vice President of Diagnostics 2
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
(Date:11/5/2014)... Rio de Janeiro, Brazil -Individuals show great diversity in ... importantly, males and females greatly differ in their perceptual ... kinds of smell tests. , Sex differences ... social behaviors and may be connected to one,s perception ... and emotions. Thus, women,s olfactory superiority has been suggested ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2
... of Environment and Hydrology (CEH) have investigated the ecology ... as parasites inside colonies of Myrmica ants, where they ... the peculiar features of this species' ecology is that ... one year. The rest are inactive in the first ...
... (HHMI) international research scholar Peter St George-Hyslop have identified ... common form of Alzheimer's disease. The research implicates a ... after age 65. , In an advance online ... George-Hyslop and colleagues connected the gene to the disease ...
... cancer-suppressing gene has been successfully delivered into the tumors ... administered lipid nanoparticle in a phase I clinical trial at ... The gene, FUS1, also was found to be active ... treated 13 patients in this first-in-human study and we've seen ...
Cached Biology News:Some caterpillers just don't want to grow up 2Scientists discover a new risk factor for Alzheimer's 2Scientists discover a new risk factor for Alzheimer's 3Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer 2
...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
... Calf Serum; U.S. sourced, ideal ... uncompromising quality; Low hemoglobin; Endotoxin: ... animals of US origin; U.S. ... seek an uncompromising quality. Low ...
NEWBORN CALF SERUM AND PLASMA...
Biology Products: